Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Section Head, Medical Oncology
Associate Director for Clinical Research
University of Virginia Cancer Center
Co-Director, Paul Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Associate Director, Scientific Services
Senior Director, Educational Strategy
Director, Program Development and Educational Impact
Associate Director, Educational Strategy
Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
USF Health OCPD staff have no relevant conflicts of interest to report.
This program is intended for physicians, nurses, clinical pharmacists, and other healthcare providers who care for patients with advanced prostate cancer.
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity.
USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 1.0 contact hour (0.1 CEU). Universal program number is as follows: 0230-9999-20-021-H01-P
Type of activity: Knowledge
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate.
ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through email@example.com.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 18, 2020, through December 17, 2021:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Focused slideset from experts on the use of radium-223 and PSMA lutetium in the treatment of metastatic castration-resistant prostate cancer, from Clinical Care Options (CCO)
On-demand webcast on PARP inhibitor combination therapies in prostate cancer featuring 3 faculty experts presented by Clinical Care Options (CCO)
Dr. Charles J. Ryan discusses the rationale and evidence for PARP inhibitor combinations in prostate cancer, from Clinical Care Options (CCO)
Downloadable PDF with highlights from a CCO podcast on PARP inhibitors and emerging combination strategies in prostate cancer.